Research programme: CNS therapeutics - CoLucid

Drug Profile

Research programme: CNS therapeutics - CoLucid

Alternative Names: COL-204

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator CoLucid Pharmaceuticals
  • Class
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Hypersomnia

Most Recent Events

  • 01 Mar 2017 CoLucid Pharmaceuticals has been acquired by Eli Lilly
  • 12 Aug 2015 Discontinued - Preclinical for Hypersomnia in USA (unspecified route)
  • 12 Aug 2015 Discontinued for CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top